SACHSE, ANDREAS,史奇斯 安卓斯,史奇斯 安卓斯,MARGOLIN, DAVID H.,玛葛林 大卫H,瑪葛林 大衛H
申请号：
TW102141784
公开号：
TWI565475B
申请日:
2007.09.10
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and 12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1 - 24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.本發明闡述一種用坎帕斯-1H(Campath-1H)治療多發性硬化症(MS)之方法,具有顯著效能及良好安全特性,提供可接受之效益/風險比。本發明特別闡述坎帕斯-1H(阿來組單抗(alemtuzumab))用於製造治療多發性硬化症(MS)之藥劑之用途,其包括坎帕斯-1H(阿來組單抗)之第一治療週期,隨後另外至少一個治療週期,其中各治療週期包括1-5個每日劑量施用連續數天,其中每日劑量>0且12毫克,且其中各治療週期與下一週期間隔至少1-24個月。本發明亦闡述包括連續1-5天投用小於12毫克/日之坎帕斯-1H之治療方案。
